SK287931B6 - Triphasic oral contraceptive - Google Patents

Triphasic oral contraceptive Download PDF

Info

Publication number: SK287931B6
Authority: SK; Slovakia
Prior art keywords: phase; estrogen; dosage units; women; study
Prior art date: 1998-12-23

Application number

SK887-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK8872001A3 (en

Inventor

Gary Shangold

Arkady Rubin

David Upmalis

Original Assignee

Ortho-Mcneil Pharmaceutical, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

1999-12-08

Publication date

2012-04-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22349144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287931(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-08 Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.

2002-03-05 Publication of SK8872001A3 publication Critical patent/SK8872001A3/sk

2012-04-03 Publication of SK287931B6 publication Critical patent/SK287931B6/sk

Links

229940127234 oral contraceptive Drugs 0.000 title claims abstract description 25
239000003539 oral contraceptive agent Substances 0.000 title claims abstract description 25
239000000262 estrogen Substances 0.000 claims abstract description 49
229940011871 estrogen Drugs 0.000 claims abstract description 49
239000000583 progesterone congener Substances 0.000 claims abstract description 37
229960000417 norgestimate Drugs 0.000 claims abstract description 25
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims abstract description 25
230000000757 progestagenic effect Effects 0.000 claims abstract description 20
230000001076 estrogenic effect Effects 0.000 claims abstract description 11
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 90
239000003433 contraceptive agent Substances 0.000 claims description 23
230000002254 contraceptive effect Effects 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 13
WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims description 9
238000000034 method Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 3
229960002568 ethinylestradiol Drugs 0.000 abstract description 63
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 66
208000032843 Hemorrhage Diseases 0.000 description 57
208000034158 bleeding Diseases 0.000 description 57
230000000740 bleeding effect Effects 0.000 description 57
239000003826 tablet Substances 0.000 description 44
230000001788 irregular Effects 0.000 description 36
230000002354 daily effect Effects 0.000 description 26
238000011282 treatment Methods 0.000 description 14
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 13
238000012360 testing method Methods 0.000 description 13
239000003814 drug Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 11
229960004976 desogestrel Drugs 0.000 description 10
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 10
238000009472 formulation Methods 0.000 description 10
230000035935 pregnancy Effects 0.000 description 9
230000000052 comparative effect Effects 0.000 description 8
229940124558 contraceptive agent Drugs 0.000 description 8
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 6
230000005906 menstruation Effects 0.000 description 6
230000027758 ovulation cycle Effects 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
229960004400 levonorgestrel Drugs 0.000 description 5
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
208000001435 Thromboembolism Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940053934 norethindrone Drugs 0.000 description 4
MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 3
229940022663 acetate Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
208000019423 liver disease Diseases 0.000 description 3
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
230000003821 menstrual periods Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
WNSDZLZVSSOOCA-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WNSDZLZVSSOOCA-WOMZHKBXSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 2
206010061178 Genital haemorrhage Diseases 0.000 description 2
206010073069 Hepatic cancer Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
229960000978 cyproterone acetate Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229960004913 dydrogesterone Drugs 0.000 description 2
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
-1 estrogen Chemical class 0.000 description 2
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
229950008385 estrone sulphate Drugs 0.000 description 2
CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 2
229940012028 ethynodiol diacetate Drugs 0.000 description 2
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 2
HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
229960002199 etretinate Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
229960005352 gestodene Drugs 0.000 description 2
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229960005280 isotretinoin Drugs 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000002483 medication Methods 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 2
229960000606 medrogestone Drugs 0.000 description 2
229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
229960004296 megestrol acetate Drugs 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
229960001858 norethynodrel Drugs 0.000 description 2
229940007688 norgestimate and ethinylestradiol Drugs 0.000 description 2
229960002831 norgestrienone Drugs 0.000 description 2
GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
229960001225 rifampicin Drugs 0.000 description 2
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
201000005060 thrombophlebitis Diseases 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010023129 Jaundice cholestatic Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
101150053343 NAD5 gene Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
241000882890 Renova Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000031271 Unwanted pregnancy Diseases 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
206010046910 Vaginal haemorrhage Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
208000024776 abnormal vaginal bleeding Diseases 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
229960002692 allylestrenol Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
229960003996 chlormadinone Drugs 0.000 description 1
VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000013502 data validation Methods 0.000 description 1
229940063223 depo-provera Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229950006690 dimethisterone Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000003248 enzyme activator Substances 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000006651 lactation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000008729 neurovascular lesion Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002667 norelgestromin Drugs 0.000 description 1
ISHXLNHNDMZNMC-XUDSTZEESA-N norelgestromin Chemical compound ON=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ISHXLNHNDMZNMC-XUDSTZEESA-N 0.000 description 1
208000013441 ocular lesion Diseases 0.000 description 1
239000003217 oral combined contraceptive Substances 0.000 description 1
239000013588 oral product Substances 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
229960001424 quinestrol Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229940059527 renova Drugs 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
238000012549 training Methods 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK887-2001A 1998-12-23 1999-12-08 Triphasic oral contraceptive SK287931B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11339498P	1998-12-23	1998-12-23
PCT/US1999/029129 WO2000038691A1 (en)	1998-12-23	1999-12-08	Triphasic oral contraceptive

Publications (2)

Publication Number	Publication Date
SK8872001A3 SK8872001A3 (en)	2002-03-05
SK287931B6 true SK287931B6 (sk)	2012-04-03

Family

ID=22349144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK887-2001A SK287931B6 (sk)	1998-12-23	1999-12-08	Triphasic oral contraceptive

Country Status (26)

Country	Link
US (2)	US6214815B1 (cs)
EP (1)	EP1140109B1 (cs)
JP (1)	JP2002533398A (cs)
KR (1)	KR100669165B1 (cs)
CN (1)	CN100408040C (cs)
AR (1)	AR028809A1 (cs)
AT (1)	ATE318605T1 (cs)
AU (1)	AU765153B2 (cs)
BR (1)	BR9916579A (cs)
CA (1)	CA2356747C (cs)
CY (1)	CY1105276T1 (cs)
CZ (1)	CZ302568B6 (cs)
DE (1)	DE69930157T2 (cs)
DK (1)	DK1140109T3 (cs)
ES (1)	ES2259481T3 (cs)
HU (1)	HU229251B1 (cs)
MX (1)	MXPA01006533A (cs)
NO (1)	NO321118B1 (cs)
NZ (1)	NZ512404A (cs)
PL (1)	PL196715B1 (cs)
PT (1)	PT1140109E (cs)
RU (1)	RU2225207C2 (cs)
SK (1)	SK287931B6 (cs)
TR (1)	TR200101826T2 (cs)
WO (1)	WO2000038691A1 (cs)
ZA (1)	ZA200106006B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5898032A (en)	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
HUP9900213A1 (hu) *	1999-02-01	2000-12-28	Gábor Bogye	Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US20060281723A1 (en) *	1999-04-16	2006-12-14	Kafrissen Michael E	Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
PT1390040E (pt) *	2001-05-18	2007-04-30	Pantarhei Bioscience Bv	Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1260225A1 (en) *	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	A pharmaceutical composition for use in hormone replacement therapy
ES2337129T3 (es) *	2001-05-23	2010-04-21	Pantarhei Bioscience B.V.	Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
US20040202713A1 (en) *	2001-05-23	2004-10-14	Van Beek Agatha Antonia Magdalena	Means and method for hormonal contraception
EP1390042B1 (en) *	2001-05-23	2007-11-28	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US8026228B2 (en) *	2001-11-15	2011-09-27	Pantarhei Bioscience B.V.	Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CN100581550C (zh) *	2001-12-05	2010-01-20	杜拉美德药物有限公司	预防怀孕和减少经期前症状的口服避孕药
CN100352445C (zh) *	2002-06-11	2007-12-05	潘塔希生物科学股份有限公司	一种皮肤护理组合物及其用途
PT1511496E (pt) *	2002-06-11	2007-01-31	Pantarhei Bioscience Bv	Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
SI1526856T1 (sl) *	2002-07-12	2008-04-30	Pantarhei Bioscience Bv	Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
JP2004140323A (ja) *	2002-08-20	2004-05-13	Sharp Corp	半導体レーザ装置およびその製造方法
SI1556058T1 (sl) *	2002-10-23	2008-02-29	Pantarhei Bioscience Bv	Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
EP1624848A4 (en)	2003-05-02	2009-02-25	Duramed Pharmaceuticals Inc	METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
CN101001631B (zh) *	2003-07-16	2014-08-06	特卫华妇女健康有限公司	利用连续给予雌激素的避孕方案的激素治疗方法
WO2005032558A1 (en) *	2003-10-01	2005-04-14	Janssen Pharmaceutica N.V.	Extended triphasic contraceptive regimens
DE102004026671A1 (de) *	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
JP2008515909A (ja) *	2004-10-07	2008-05-15	デュラメドファーマシューティカルズインコーポレーティッド	上昇用量延長サイクル療法を利用するホルモン処置の方法
US20070111975A1 (en) *	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070077269A1 (en) *	2005-10-04	2007-04-05	Woodward John R	Method of birth control and hormone regulation
US20070254025A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20070254858A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
CN101489563A (zh) *	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
ATE473746T1 (de) *	2007-01-08	2010-07-15	Pantarhei Bioscience Bv	Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
DE102007011486A1 (de) *	2007-03-07	2008-09-11	Grünenthal GmbH	Arzneimittel umfassend wenigstens ein Gestagen
US20100178323A1 (en)	2007-07-10	2010-07-15	Agis Kydonieus	Dermal Delivery Device
ES2734510T3 (es)	2008-10-08	2019-12-10	Agile Therapeutics Inc	Administración transdérmica
CA2740004A1 (en)	2008-10-08	2010-04-15	Agile Therapeutics, Inc.	Transdermal delivery
US9198919B2 (en)	2008-10-08	2015-12-01	Agile Therapeutics, Inc.	Contraceptive transdermal delivery of hormones
EP2410859A4 (en)	2009-03-27	2013-03-13	Agile Therapeutics Inc	TRANSDERMAL ADMINISTRATION
US8951996B2 (en)	2011-07-28	2015-02-10	Lipocine Inc.	17-hydroxyprogesterone ester-containing oral compositions and related methods
AU2016284459B2 (en)	2015-06-22	2021-12-23	Lipocine Inc.	17-hydroxyprogesterone ester-containing oral compositions and related methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3568828A (en)	1967-03-01	1971-03-09	Squibb & Sons Inc	Modified sequential oral contraceptive
US3836651A (en)	1972-02-22	1974-09-17	Biolog Concepts Inc	Novel oral contraceptive combination
DE2310963A1 (de)	1972-04-14	1974-09-05	Schering Ag	Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3969502A (en)	1972-04-14	1976-07-13	Schering Aktiengesellschaft	Method for contraception by the administration of sequential contraceptive preparations
US3932635A (en)	1972-04-24	1976-01-13	Syntex Corporation	Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
DE2365103C3 (de)	1973-12-21	1980-08-28	Schering Ag, 1000 Berlin Und 4619 Bergkamen	V erwendung von Hormonen zur Kontrazeption
US4291028A (en)	1977-12-30	1981-09-22	Nichols Vorys	Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
NL8001593A (nl)	1980-03-18	1981-10-16	Akzo Nv	Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en)	1981-08-10	1983-06-28	Syntex Pharmaceuticals International Ltd.	Method of contraception using peak progestogen dosage
US4921843A (en)	1988-10-20	1990-05-01	Pasquale Samuel A	Contraception system and method
USRE35724E (en)	1982-04-28	1998-02-03	Bio-Technology General Corp.	Contraception system and method
US4544554A (en)	1983-09-26	1985-10-01	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4628051A (en)	1983-09-26	1986-12-09	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4530839A (en)	1983-09-26	1985-07-23	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4616006A (en)	1983-09-26	1986-10-07	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4962098A (en)	1987-06-15	1990-10-09	Warner-Lambert Company	Graduated estrogen contraceptive
US5023084A (en)	1986-12-29	1991-06-11	Rutgers, The State University Of New Jersey	Transdermal estrogen/progestin dosage unit, system and process
US5276022A (en)	1987-09-24	1994-01-04	Jencap Research Ltd.	Hormone preparation and method
US4948593A (en)	1989-05-15	1990-08-14	Alza Corporation	Osmotic dosage form comprising an estrogen and a progestogen
IE71203B1 (en)	1990-12-13	1997-02-12	Akzo Nv	Low estrogen oral contraceptives
IE62665B1 (en)	1990-12-17	1995-02-22	Akzo Nv	Contraceptive regimen
US5453279A (en)	1992-04-21	1995-09-26	Tbs Laboratories, Inc.	Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5759577A (en) *	1995-01-17	1998-06-02	American Home Products Corporation	Controlled release of steroids from sugar coatings
DE19513662A1 (de) *	1995-04-08	1996-10-10	Schering Ag	Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) *	1995-06-28	1997-01-02	Schering Ag	Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5747480A (en)	1996-05-08	1998-05-05	American Home Products Corporation	Oral contraceptive

1999
- 1999-06-09 US US09/328,764 patent/US6214815B1/en not_active Expired - Lifetime
- 1999-12-08 CZ CZ20012184A patent/CZ302568B6/cs not_active IP Right Cessation
- 1999-12-08 WO PCT/US1999/029129 patent/WO2000038691A1/en not_active Ceased
- 1999-12-08 JP JP2000590643A patent/JP2002533398A/ja active Pending
- 1999-12-08 MX MXPA01006533A patent/MXPA01006533A/es active IP Right Grant
- 1999-12-08 CA CA002356747A patent/CA2356747C/en not_active Expired - Fee Related
- 1999-12-08 DE DE69930157T patent/DE69930157T2/de not_active Expired - Lifetime
- 1999-12-08 AT AT99963049T patent/ATE318605T1/de active
- 1999-12-08 PT PT99963049T patent/PT1140109E/pt unknown
- 1999-12-08 RU RU2001117204/15A patent/RU2225207C2/ru active
- 1999-12-08 NZ NZ512404A patent/NZ512404A/en not_active IP Right Cessation
- 1999-12-08 DK DK99963049T patent/DK1140109T3/da active
- 1999-12-08 CN CNB998161578A patent/CN100408040C/zh not_active Expired - Lifetime
- 1999-12-08 ES ES99963049T patent/ES2259481T3/es not_active Expired - Lifetime
- 1999-12-08 KR KR1020017007809A patent/KR100669165B1/ko not_active Expired - Lifetime
- 1999-12-08 PL PL349629A patent/PL196715B1/pl unknown
- 1999-12-08 BR BR9916579-1A patent/BR9916579A/pt not_active Application Discontinuation
- 1999-12-08 AU AU19365/00A patent/AU765153B2/en not_active Expired
- 1999-12-08 EP EP99963049A patent/EP1140109B1/en not_active Expired - Lifetime
- 1999-12-08 HU HU0104680A patent/HU229251B1/hu unknown
- 1999-12-08 TR TR2001/01826T patent/TR200101826T2/xx unknown
- 1999-12-08 SK SK887-2001A patent/SK287931B6/sk not_active IP Right Cessation
- 1999-12-22 AR ARP990106694A patent/AR028809A1/es unknown
2001
- 2001-02-13 US US09/782,420 patent/US20010044429A1/en not_active Abandoned
- 2001-06-22 NO NO20013144A patent/NO321118B1/no not_active IP Right Cessation
- 2001-07-20 ZA ZA200106006A patent/ZA200106006B/en unknown
2006
- 2006-05-17 CY CY20061100638T patent/CY1105276T1/el unknown

Also Published As

Publication number	Publication date
NZ512404A (en)	2003-08-29
HUP0104680A2 (hu)	2002-04-29
CN1334734A (zh)	2002-02-06
HUP0104680A3 (en)	2002-06-28
CA2356747C (en)	2005-09-27
NO20013144D0 (no)	2001-06-22
EP1140109B1 (en)	2006-03-01
US6214815B1 (en)	2001-04-10
US20010044429A1 (en)	2001-11-22
NO20013144L (no)	2001-08-23
ATE318605T1 (de)	2006-03-15
CY1105276T1 (el)	2010-03-03
DK1140109T3 (da)	2006-05-15
HU229251B1 (en)	2013-10-28
PT1140109E (pt)	2006-05-31
CZ20012184A3 (cs)	2003-01-15
CN100408040C (zh)	2008-08-06
KR20010081087A (ko)	2001-08-25
AR028809A1 (es)	2003-05-28
BR9916579A (pt)	2001-10-02
NO321118B1 (no)	2006-03-20
CA2356747A1 (en)	2000-07-06
RU2225207C2 (ru)	2004-03-10
PL196715B1 (pl)	2008-01-31
CZ302568B6 (cs)	2011-07-13
DE69930157D1 (de)	2006-04-27
AU1936500A (en)	2000-07-31
ES2259481T3 (es)	2006-10-01
ZA200106006B (en)	2002-10-21
SK8872001A3 (en)	2002-03-05
KR100669165B1 (ko)	2007-01-17
EP1140109A1 (en)	2001-10-10
WO2000038691A1 (en)	2000-07-06
AU765153B2 (en)	2003-09-11
DE69930157T2 (de)	2006-08-31
MXPA01006533A (es)	2002-06-04
TR200101826T2 (tr)	2001-12-21
JP2002533398A (ja)	2002-10-08

Legal Events

Date	Code	Title	Description
2020-02-04	MK4A	Patent expired	Expiry date: 20191208

Publication	Publication Date	Title
SK287931B6 (sk)	2012-04-03	Triphasic oral contraceptive
CA2188907C (en)	2001-02-27	Combination compound for contraception based on natural estrogen
US8338396B2 (en)	2012-12-25	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
RU2122854C1 (ru)	1998-12-10	Комбинированный препарат для контрацепции, фармацевтическая упаковка для контрацепции
JP3314207B2 (ja)	2002-08-12	ホルモン製剤及び方法
US20050113350A1 (en)	2005-05-26	Extended use combination comprising estrogens and progestins
CN1863537A (zh)	2006-11-15	延长的三阶段避孕法
US20050038006A1 (en)	2005-02-17	Triphasic oral contraceptive
DI CARLO et al.	2021	Current and future hormonal contraception in Italy: results from an Italian consensus expert meeting.